



Kura Oncology to Participate in Three Upcoming Investor Conferences

February 25, 2025

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:

- A fireside chat at the TD Cowen Health Care Conference in Boston at 2:30 p.m. ET / 11:30 a.m. PT on March 4, 2025;
- A fireside chat at the Barclays Global Healthcare Conference in Miami at 9:30 a.m. ET / 6:30 a.m. PT on March 11, 2025; and
- A fireside chat at the Leerink Partners Global Biopharma Conference in Miami at 8:00 a.m. ET / 5:00 a.m. PT on March 12, 2025.

Live audio webcasts will be available in the Investors section of Kura's website at <https://kuraoncology.com/>, with archived replays available following all three events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (the "FDA") for the treatment of relapsed/refractory ("R/R") NPM1-mutant acute myeloid leukemia ("AML"). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at <https://kuraoncology.com/> and follow us on [X](#) and [LinkedIn](#).

Contacts

Investors:

Patti Bank

Managing Director

(415) 513-1284

patti.bank@icrhealthcare.com

Media:

Alexandra Weingarten

Associate Director, Corporate Communications

& Investor Relations

(858) 500-8822

alexandra@kuraoncology.com



Source: Kura Oncology, Inc.